P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents — Ioannis Ntanasis‐Stathopoulos (2022) | RDL Network
P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents
Ioannis Ntanasis‐Stathopoulos, Vangelis Karalis, Maria Gavriatopoulou, Panagiotis Malandrakis, Aimilia D. Sklirou, Evangelos Eleutherakis‐Papaiakovou, Magdalini Migkou, Μαρία Ρούσσου, Despina Fotiou, Harry Alexopoulos, Foteini Theodorakakou, Efstathios Kastritis, Vassiliki A. Iconomidou, Ioannis P. Trougakos, Meletios A Dimopoulos, Evangelos Terpos
Evangelos Terpos, Despina Fotiou, Vangelis Karalis, Ioannis Ntanasis‐Stathopoulos, Aimilia D. Sklirou, Maria Gavriatopoulou, Panagiotis Malandrakis, Vassiliki A. Iconomidou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.